Biotech Funding Roundup: HI-Bio’s Haul, Concerto’s Cash, Lusaris’s Launch & More

Nov 6, 2022 | Featured News

Tissue regeneration biotech Novadip Biosciences raised €40 million. The cash will go toward two clinical-stage programs: an allogeneic bone union therapeutic called NVD-X3 and NVD-003, an autologous bone engraftment product. The cash breaks down to €24 million in equity financing and €16 million in non-dilutive financing.